Read this company snapshot
Daily valuation snapshot
Lexicon Pharmaceuticals, Inc.: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.68
- Market capitalization (USD)
- $747,525,969.12
- Price / earnings (TTM)
- Not reported
- Price / book
- 4.28
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research LXRX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research LXRX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing LXRX with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.68 |
| Market capitalization (USD) | $747,525,969.12 |
| Price / earnings (TTM) | Not reported |
| Price / book | 4.28 |
No matching rows. Clear the filter to see all records.
Read LXRX's valuation metrics
Company size
Lexicon Pharmaceuticals, Inc.'s recorded market capitalization is $747,525,969.12. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
LXRX's recorded price-to-book ratio is 4.28. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Lexicon Pharmaceuticals, Inc. with Aurora
Use the snapshot above to ask a specific question about LXRX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow LXRX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.